Effect of Nicotine 6 mg Gum on Urges to Smoke, a Randomized Clinical Trial

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2019 Nov 23

PMID 31753009

Citations 5

Authors

Anna Hansson

Thomas Rasmussen

Roland Perfekt

Elin Hall

Holger Kraiczi

Affiliations

Soon will be listed here.

Abstract

Background: Ability to manage urges to smoke is fundamental to maximizing the chances of success in smoking cessation. Previous studies have linked a higher dose of nicotine in nicotine replacement therapy to a higher success rate for smoking cessation. Thus, this study was performed to compare relief of urges to smoke, up until 5 h following treatment with a new 6 mg nicotine gum versus currently marketed 4 mg nicotine gum.

Methods: This was a randomized crossover clinical study. Following 12 h of abstinence from smoking, either one 6 mg or one 4 mg nicotine gum was given to 240 healthy adult smokers. Thereafter, urges to smoke were scored on a 100 mm Visual Analogue Scale repeatedly over 5 h.

Results: The reductions in urges to smoke over the first 1 and 3 h after administration were statistically significantly greater with 6 mg than 4 mg gum, (p < 0.005). A 50% reduction in perceived urges to smoke was reached in 9.4 min with 6 mg gum compared to 16.2 min with 4 mg gum (median values). The median duration of a 50% or more reduction in VAS urges to smoke score was 111 min with the 6 mg gum, versus 74 min for the 4 mg gum.

Conclusion: This study provides evidence that the 6 mg nicotine gum provided a greater reduction, faster and longer relief of urges to smoke than the 4 mg nicotine gum.

Trial Registration: EudraCT Number: 2010-023268-42. Study was first entered in EudraCT 2011-02-23.

Citing Articles

Effects of tobacco product use on oral health and the role of oral healthcare providers in cessation: A narrative review.

Gajendra S, McIntosh S, Ghosh S Tob Induc Dis. 2023; 21:12.

PMID: 36741542 PMC: 9875717. DOI: 10.18332/tid/157203.

TOBACCO USE DISORDER AND DUAL DISORDERS Joint statement by the Spanish Psychiatry Society and the Spanish Dual Disorders Society.

Nestor S, Carlos P, Cristina P, Jose M, Ignacio B, Pilar S Actas Esp Psiquiatr. 2022; 50(Supplement):77-138.

PMID: 35731182 PMC: 11095114.

A randomised, crossover, clinical study to assess nicotine pharmacokinetics and subjective effects of the BIDI stick ENDS compared with combustible cigarettes and a comparator ENDS in adult smokers.

Fearon I, Gilligan K, Seltzer R, McKinney W Harm Reduct J. 2022; 19(1):57.

PMID: 35655314 PMC: 9160848. DOI: 10.1186/s12954-022-00638-0.

An Open-Label, Randomized, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers.

Goldenson N, Fearon I, Buchhalter A, Henningfield J Nicotine Tob Res. 2021; 23(6):947-955.

PMID: 33486526 PMC: 8628869. DOI: 10.1093/ntr/ntab001.

Nicotine replacement therapy: A friend or foe.

Devi R, Barman D, Sinha S, Hazarika S, Das S J Family Med Prim Care. 2020; 9(6):2615-2620.

PMID: 32984096 PMC: 7491776. DOI: 10.4103/jfmpc.jfmpc_313_20.

References

Wewers M, Rachfal C, Ahijevych K . A psychometric evaluation of a visual analogue scale of craving for cigarettes. West J Nurs Res. 1990; 12(5):672-81. DOI: 10.1177/019394599001200508. View

Zinser M, Fiore M, Davidson R, Baker T . Manipulating smoking motivation: impact on an electrophysiological index of approach motivation. J Abnorm Psychol. 1999; 108(2):240-54. DOI: 10.1037//0021-843x.108.2.240. View

Wadgave U, Nagesh L . Nicotine Replacement Therapy: An Overview. Int J Health Sci (Qassim). 2016; 10(3):425-35. PMC: 5003586. View

Niaura R, Sayette M, Shiffman S, Glover E, Nides M, Shelanski M . Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005; 100(11):1720-30. DOI: 10.1111/j.1360-0443.2005.01218.x. View

Shiffman S, Hickcox M, Paty J, Gnys M, Richards T, Kassel J . Individual differences in the context of smoking lapse episodes. Addict Behav. 1998; 22(6):797-811. DOI: 10.1016/s0306-4603(97)00063-4. View

Tonnesen P, Paoletti P, Gustavsson G, Russell M, Saracci R, Gulsvik A . Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999; 13(2):238-46. DOI: 10.1034/j.1399-3003.1999.13b04.x. View

Piasecki T . Relapse to smoking. Clin Psychol Rev. 2005; 26(2):196-215. DOI: 10.1016/j.cpr.2005.11.007. View

Hartmann-Boyce J, Chepkin S, Ye W, Bullen C, Lancaster T . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018; 5:CD000146. PMC: 6353172. DOI: 10.1002/14651858.CD000146.pub5. View

Swan G, Ward M, Jack L . Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav. 1996; 21(4):481-90. DOI: 10.1016/0306-4603(95)00070-4. View

10.

Garvey A, Kinnunen T, Nordstrom B, Utman C, Doherty K, Rosner B . Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res. 2000; 2(1):53-63. DOI: 10.1080/14622200050011303. View

11.

Piper M, Federmen E, McCarthy D, Bolt D, Smith S, Fiore M . Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol. 2008; 117(1):94-105. DOI: 10.1037/0021-843X.117.1.94. View

12.

. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008; 53(9):1217-22. View

13.

Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom K . Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest. 1995; 108(2):447-51. DOI: 10.1378/chest.108.2.447. View

14.

Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnersen A, Forchammer H . Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict Behav. 1988; 13(1):17-27. DOI: 10.1016/0306-4603(88)90021-4. View

15.

Benowitz N . Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008; 83(4):531-41. DOI: 10.1038/clpt.2008.3. View

16.

Thewissen R, Snijders S, Havermans R, van den Hout M, Jansen A . Renewal of cue-elicited urge to smoke: implications for cue exposure treatment. Behav Res Ther. 2005; 44(10):1441-9. DOI: 10.1016/j.brat.2005.10.010. View

17.

Balmford J, Borland R, Hammond D, Cummings K . Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2010; 13(2):94-102. PMC: 3028191. DOI: 10.1093/ntr/ntq215. View

18.

Mogg K, Bradley B . Selective processing of smoking-related cues in smokers: manipulation of deprivation level and comparison of three measures of processing bias. J Psychopharmacol. 2002; 16(4):385-92. DOI: 10.1177/026988110201600416. View

19.

Hansson A, Rasmussen T, Kraiczi H . Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. Nicotine Tob Res. 2016; 19(4):477-483. DOI: 10.1093/ntr/ntw211. View

20.

Ferguson S, Shiffman S, Gwaltney C . Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol. 2006; 74(6):1153-61. DOI: 10.1037/0022-006X.74.6.1153. View